Company news

TELA Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

TELA Bio to Announce Third Quarter 2026 Financial Results

October 27, 2026

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

October 5, 2026

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

August 31, 2026

TELA Bio Reports Second Quarter 2026 Financial Results

August 10, 2026

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

August 6, 2026

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

August 4, 2026

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

July 29, 2026

TELA Bio to Announce Second Quarter 2026 Financial Results

July 20, 2026

TELA Bio Reports First Quarter 2026 Financial Results

May 12, 2026

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

April 29, 2026

TELA Bio to Announce First Quarter 2026 Financial Results

April 21, 2026

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

March 23, 2026

TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results

March 9, 2026

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 23, 2026

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 19, 2025

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants

November 13, 2025

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility

November 13, 2025

TELA Bio to Announce Third Quarter 2025 Financial Results

November 4, 2025

TELA Bio Appoints William Plovanic to Board of Directors

November 3, 2025

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

October 9, 2025

TELA Bio Reports Second Quarter 2025 Financial Results

August 11, 2025

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 23, 2025

TELA Bio to Announce Second Quarter 2025 Financial Results

July 21, 2025

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025

TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

June 3, 2025

TELA Bio Appoints Jeffrey Blizard as President

June 2, 2025

TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 22, 2025

TELA Bio Reports First Quarter 2025 Financial Results

May 8, 2025

TELA Bio to Announce First Quarter 2025 Financial Results

April 17, 2025

TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery

March 31, 2025

TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 20, 2025

TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference

November 18, 2024

TELA Bio Reports Third Quarter 2024 Financial Results

November 6, 2024

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

October 23, 2024

TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

October 22, 2024

TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

October 21, 2024

TELA Bio to Announce Third Quarter 2024 Financial Results

October 16, 2024

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance

August 11, 2024

TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference

July 24, 2024

TELA Bio to Announce Second Quarter 2024 Financial Results

July 21, 2024

TELA Bio Appoints Jeffrey Blizard to its Board of Directors

June 3, 2024

TELA Bio Appoints Greg Firestone as Chief Commercial Officer

May 19, 2024

TELA Bio Reports First Quarter 2024 Financial Results

May 8, 2024

TELA Bio to Announce First Quarter 2024 Financial Results

April 24, 2024

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

April 14, 2024

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

April 7, 2024

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

March 20, 2024

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

March 20, 2024

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX

March 19, 2024

Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 29 decks. Every deck is listed under its year.